Ideaya Biosciences Company Insiders

IDYA Stock  USD 18.39  0.05  0.27%   
Ideaya Biosciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Ideaya Biosciences suggests that vertually all insiders are panicking. Ideaya Biosciences employs about 131 people. The company is managed by 16 executives with a total tenure of roughly 306 years, averaging almost 19.0 years of service per executive, having 8.19 employees per reported executive.

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-05-29Michael Anthony WhiteDisposed 28500 @ 36.24View
2024-05-16Yujiro S HataDisposed 34433 @ 41.81View
2024-05-14Yujiro S HataDisposed 56711 @ 41.61View
Monitoring Ideaya Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.

Ideaya Biosciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ideaya Biosciences' future performance. Based on our forecasts, it is anticipated that Ideaya will maintain a workforce of about 130 employees by April 2025.
 
Covid

Ideaya Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.2305) % which means that it has lost $0.2305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3267) %, meaning that it created substantial loss on money invested by shareholders. Ideaya Biosciences' management efficiency ratios could be used to measure how well Ideaya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.26. In addition to that, Return On Capital Employed is expected to decline to -0.32. At present, Ideaya Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 422 M, whereas Return On Tangible Assets are forecasted to decline to (0.26).
The current year's Common Stock Shares Outstanding is expected to grow to about 85.8 M, whereas Net Loss is forecasted to decline to (55.4 M).

Ideaya Biosciences Workforce Comparison

Ideaya Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,891. Ideaya Biosciences holds roughly 131 in number of employees claiming about 3% of equities under Health Care industry.

Ideaya Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ideaya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ideaya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ideaya Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
7.0
7
1
 1,105,808 
 12,808 
2024-06-01
0.8667
13
15
 370,384 
 460,484 
2024-03-01
0.7143
10
14
 1,165,500 
 356,000 
2023-12-01
0.4444
4
9
 100,163 
 192,326 
2023-09-01
0.25
6
24
 19,322 
 206,894 
2023-06-01
1.625
13
8
 153,686 
 28,571 
2022-03-01
3.0
3
1
 445,000 
 63,750 
2021-12-01
0.6667
2
3
 201,500 
 3,000 
2021-09-01
0.4
10
25
 44,500 
 111,500 
2021-06-01
1.375
11
8
 78,359 
 23,000 
2021-03-01
0.8667
13
15
 505,000 
 64,210 
2020-12-01
0.4286
3
7
 16,194 
 817,729 
2020-06-01
1.25
20
16
 255,314 
 71,060 
2020-03-01
6.0
6
1
 465,000 
 5,000 
2019-09-01
2.25
9
4
 63,092 
 37,342 
2019-06-01
0.7
28
40
 14,201,011 
 12,827,489 

Ideaya Biosciences Notable Stakeholders

An Ideaya Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ideaya Biosciences often face trade-offs trying to please all of them. Ideaya Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ideaya Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Yujiro HataPresident, CoFounderProfile
Mick OQuigleyChief DevelopmentProfile
Stu DormanChief OfficerProfile
Paul StoneCFO VPProfile
JD EsqChief SecretaryProfile
Matthew MDVP OncologyProfile
Esq JDGen VPProfile
Stuart DormanChief OfficerProfile
Joshua BleharskiChief OfficerProfile
Michael WhiteChief OfficerProfile
Daniel SimonChief OfficerProfile
Andres CPASenior OfficerProfile
Francine ZelayaVice ResourcesProfile
Douglas SnyderSenior CounselProfile
Jeffrey HagerCo FounderProfile
Paul BarsantiChief OfficerProfile

About Ideaya Biosciences Management Performance

The success or failure of an entity such as Ideaya Biosciences often depends on how effective the management is. Ideaya Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ideaya management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ideaya management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.24)(0.26)
Return On Capital Employed(0.30)(0.32)
Return On Assets(0.24)(0.26)
Return On Equity(0.26)(0.25)
Please note, the presentation of Ideaya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ideaya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ideaya Biosciences' management manipulating its earnings.

Ideaya Biosciences Workforce Analysis

Traditionally, organizations such as Ideaya Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ideaya Biosciences within its industry.

Ideaya Biosciences Manpower Efficiency

Return on Ideaya Biosciences Manpower

Revenue Per Employee53.4K
Revenue Per Executive437.5K
Net Loss Per Employee2.1M
Net Loss Per Executive17.2M
Working Capital Per Employee4.9M
Working Capital Per Executive40.2M

Complementary Tools for Ideaya Stock analysis

When running Ideaya Biosciences' price analysis, check to measure Ideaya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ideaya Biosciences is operating at the current time. Most of Ideaya Biosciences' value examination focuses on studying past and present price action to predict the probability of Ideaya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ideaya Biosciences' price. Additionally, you may evaluate how the addition of Ideaya Biosciences to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stocks Directory
Find actively traded stocks across global markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets